Single therapy offers improved survival in younger patients with limited brain metastases
the ONA take:
A study that analyzed patient data from the three largest randomized clinical trials of stereotactic radiosurgery (SRS) and whole brain radiation therapy (WBRT) found that in patients with cancer who are ages 50 years and younger should receive SRS without WBRT.
The meta-analysis examined data from a total of 364 patients from an Asian trial (JROSG99-1), published in 2006; a North American trial (MDACC NCT00548756), published in 2009; and a European trial (EORTC 22952-26001), published in 2011.
The data showed that SRS alone yielded improved overall survival (OS) in patients ages 50 years and younger. Median survival for these patients was 13.6 months after treatment with SRS alone, whereas patients in the same age group who received SRS plus WBRT had a median survival of 8.2 months.
Patients older than 50 years who underwent SRS along had a median survival of 10.1 months, and 8.6 months for those who received SRS plus WBRT.
The researchers reported expecting to see improved survival in patients who received therapy combining SRS and WBRT.
However, these data clearly demonstrated SRS alone offered benefits for younger patients with limited metastases.
Data clearly demonstrated stereotactic radiosurgery alone offered benefits for younger patients with limited metastases.
Sign Up for Free e-newsletters
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Accurate Understanding of Capacity May Improve Workflow, Efficiency in Infusion Suite
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|